{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:07:01Z","timestamp":1785942421764,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.7759\/cureus.114007","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:28:56Z","timestamp":1785940136000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunohistochemical Expression of Programmed Death-Ligand 1 (PD-L1) in Breast Carcinoma and Its Correlation With Estrogen Receptor, Progesterone Receptor and HER2\/neu Status: A Single-Centre Study From Central India"],"prefix":"10.7759","author":[{"given":"Piyush","family":"Dubey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12661","article-title":"Epidemiology of breast cancer in Indian women","volume":"13","author":"Malvia S","year":"2017","unstructured":"Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017, 13:289-95. 10.1111\/ajco.12661","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00122","article-title":"Cancer Statistics, 2020: report from National Cancer Registry Programme, India","volume":"6","author":"Mathur P","year":"2020","unstructured":"Mathur P, Sathishkumar K, Chaturvedi M, et al.. Cancer Statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020, 6:1063-75. 10.1200\/GO.20.00122","journal-title":"JCO Glob Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.07.013","article-title":"Alarming burden of triple-negative breast cancer in India","volume":"18","author":"Thakur KK","year":"2018","unstructured":"Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming burden of triple-negative breast cancer in India. Clin Breast Cancer. 2018, 18:e393-9. 10.1016\/j.clbc.2017.07.013","journal-title":"Clin Breast Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck N","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, et al.. Breast cancer. Nat Rev Dis Primers. 2019, 5:66. 10.1038\/s41572-019-0111-2","journal-title":"Nat Rev Dis Primers"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou CM","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, et al.. Molecular portraits of human breast tumours. Nature. 2000, 406:747-52. 10.1038\/35021093","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini G","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016, 13:674-90. 10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong H","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al.. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002, 8:793-800. 10.1038\/nm730","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens LA","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH, et al.. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021, 32:983-93. 10.1016\/j.annonc.2021.05.355","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid P","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, et al.. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022, 386:556-67. 10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3529","article-title":"Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis","volume":"362","author":"Shen X","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018, 362:k3529. 10.1136\/bmj.k3529","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer","volume":"113","author":"Rugo HS","year":"2021","unstructured":"Rugo HS, Loi S, Adams S, et al.. PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab-paclitaxel-treated advanced triple-negative breast cancer. J Natl Cancer Inst. 2021, 113:1733-43. 10.1093\/jnci\/djab108","journal-title":"J Natl Cancer Inst"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst S","year":"2014","unstructured":"Muenst S, Schaerli AR, Gao F, et al.. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014, 146:15-24. 10.1007\/s10549-014-2988-5","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan PH","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, et al.. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020, 77:181-5. 10.1111\/his.14091","journal-title":"Histopathology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston CW","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19:403-10. 10.1111\/j.1365-2559.1991.tb00229.x","journal-title":"Histopathology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer","volume":"25","author":"Giuliano AE","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018, 25:1783-5. 10.1245\/s10434-018-6486-6","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001215)89:12<2637::aid-cncr17>3.0.co;2-b","article-title":"COX-2 is expressed in human pulmonary, colonic, and mammary tumors","volume":"89","author":"Soslow RA","year":"2000","unstructured":"Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000, 89:2637-45. 10.1002\/1097-0142(20001215)89:12&lt;2637::aid-cncr17&gt;3.0.co;2-b","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond ME","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, et al.. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010, 134:e48-72. 10.5858\/134.7.e48","journal-title":"Arch Pathol Lab Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff AC","year":"2018","unstructured":"Wolff AC, Hammond ME, Allison KH, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018, 142:1364-82. 10.5858\/arpa.2018-0902-SA","journal-title":"Arch Pathol Lab Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas","volume":"20","author":"Schalper KA","year":"2014","unstructured":"Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014, 20:2773-82. 10.1158\/1078-0432.CCR-13-2702","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier R","year":"2015","unstructured":"Sabatier R, Finetti P, Mamessier E, et al.. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015, 6:5449-64. 10.18632\/oncotarget.3216","journal-title":"Oncotarget"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020229","article-title":"PD-L1 protein expression in Middle Eastern breast cancer predicts favorable outcome in triple-negative breast cancer","volume":"10","author":"Parvathareddy SK","year":"2021","unstructured":"Parvathareddy SK, Siraj AK, Ahmed SO, et al.. PD-L1 protein expression in Middle Eastern breast cancer predicts favorable outcome in triple-negative breast cancer. Cells. 2021, 10:10.3390\/cells10020229","journal-title":"Cells"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh H","year":"2006","unstructured":"Ghebeh H, Mohammed S, Al-Omair A, et al.. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006, 8:190-8. 10.1593\/neo.05733","journal-title":"Neoplasia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12753","article-title":"Prognostic value of PD-L1 in breast cancer: a meta-analysis","volume":"23","author":"Wang C","year":"2017","unstructured":"Wang C, Zhu H, Zhou Y, et al.. Prognostic value of PD-L1 in breast cancer: a meta-analysis. Breast J. 2017, 23:436-43. 10.1111\/tbj.12753","journal-title":"Breast J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz A","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, et al.. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017, 19:1189-201. 10.1016\/j.celrep.2017.04.031","journal-title":"Cell Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.09.006","article-title":"Prognostic significance of PD-L1 and PD-L2 in breast cancer","volume":"47","author":"Baptista MZ","year":"2016","unstructured":"Baptista MZ, Sarian LO, Derchain SF, Pinto GA, Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016, 47:78-84. 10.1016\/j.humpath.2015.09.006","journal-title":"Hum Pathol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1509820","article-title":"Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival","volume":"7","author":"Sobral-Leite M","year":"2018","unstructured":"Sobral-Leite M, Van de Vijver K, Michaut M, et al.. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018, 7:e1509820. 10.1080\/2162402X.2018.1509820","journal-title":"Oncoimmunology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2015.07.006","article-title":"Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer","volume":"16","author":"Park IH","year":"2016","unstructured":"Park IH, Kong SY, Ro JY, et al.. Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer. Clin Breast Cancer. 2016, 16:51-8. 10.1016\/j.clbc.2015.07.006","journal-title":"Clin Breast Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030636","article-title":"Crosstalk between HER2 and PD-1\/PD-L1 in breast cancer: from clinical applications to mathematical models","volume":"12","author":"Padmanabhan R","year":"2020","unstructured":"Padmanabhan R, Kheraldine HS, Meskin N, Vranic S, Al Moustafa AE. Crosstalk between HER2 and PD-1\/PD-L1 in breast cancer: from clinical applications to mathematical models. Cancers (Basel). 2020, 12:10.3390\/cancers12030636","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52944-6","article-title":"Clinicopathological values of PD-L1 expression in HER2-positive breast cancer","volume":"9","author":"Kurozumi S","year":"2019","unstructured":"Kurozumi S, Inoue K, Matsumoto H, et al.. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep. 2019, 9:16662. 10.1038\/s41598-019-52944-6","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516462-immunohistochemical-expression-of-programmed-death-ligand-1-pd-l1-in-breast-carcinoma-and-its-correlation-with-estrogen-receptor-progesterone-receptor-and-her2neu-status-a-single-centre-study-from-central-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:28:57Z","timestamp":1785940137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516462-immunohistochemical-expression-of-programmed-death-ligand-1-pd-l1-in-breast-carcinoma-and-its-correlation-with-estrogen-receptor-progesterone-receptor-and-her2neu-status-a-single-centre-study-from-central-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.114007","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}